Author: Artan, R.

Source: Journal of Chemotherapy, Number 2, April 2005 , pp. 198-202(5)

Publisher: Maney Publishing

Abstract:

We investigated the efficacy of lamivudine treatment in inducing a primary and sustained response in naïve pediatric patients with immune-tolerant chronic hepatitis B viral (HBV) infection. Lamivudine was used (maximum 100 mg/day) for an average of 35 months (16-60 months) for 17 patients, while 6 patients were untreated. All the treated patients became HBV-DNA negative in the twelfth month of therapy with an average of 7 months, however none of them had a sustained virological response. They all became HBV-DNA positive by the twentieth month on average. One patient had significant improvement in liver histology. No side effects were observed. Spontaneous HBV-DNA clearance or HBe seroconversion was obtained in none of the untreated cases. This study suggests that lamivudine cannot induce complete viral control in HBV pediatric immune-tolerant patients.

Keywords: Hepatitis B; lamivudine; hepatitis B virus; immune tolerance; children

Document Type: Research Article

Publication date: 2005-04-01

More about this publication?

• Editorial Board
• Information for Authors
• Submit a Paper
• Subscribe to this Title
• Information for Advertisers
• Terms & Conditions
• Top Articles
• Abstracted in
• Sign up for e-alerts
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• By this author: Artan, R.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers